YD Bio Limited - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
YDES Nasdaq 3850 www.ydesgroup.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for YD Bio Limited

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs - Oct 20th, 2026 6:00 am
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment - Oct 6th, 2026 6:00 am
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 - Aug 31st, 2026 4:00 pm
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Aug 25th, 2026 6:00 am
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Aug 11th, 2026 6:00 am
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research - Aug 4th, 2026 6:00 am
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - Jul 28th, 2026 6:00 am
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - Jul 23rd, 2026 6:00 am
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - Jul 2nd, 2026 6:00 am
YD Bio Limited Reports Full Year 2025 Financial Results - Apr 30th, 2026 4:00 pm
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States - Mar 31st, 2026 6:00 am
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem - Mar 17th, 2026 6:00 am
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Jan 13th, 2026 8:00 am
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development - Jan 6th, 2026 7:00 am
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Jan 5th, 2026 7:00 am